November 10, 2003
Source: Decision Resources, Inc.
Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that inflammatory disorders represent the largest opportunity for future biotech development. According to the new report from Decision Resources entitled Biotech to 2012: Key Therapeutic Areas, at the end of the 1990s, biotech success stories were mostly limited to relatively rare conditions such as hematological disorders. Today, however, sufficient critical mass has been accumulated in fields such as inflammation and cancer, where life-threatening or disabling conditions affect huge populations. In 2012, the bulk of pharmaceutical biotechnology sales will likely come from these therapeutic areas of chronic and progressive disease.
"The spectrum of inflammatory diseases targeted by biotechnology is extremely broad. The therapy areas where biotechnology has begun to make the most significant inroads (with considerable recent success) include allergic asthma, rheumatoid arthritis, inflammatory bowel disease, psoriasis, and multiple sclerosis (MS)," said Tracy DeGregorio, director of DR Industry Reports at Decision Resources. "For example, although there are no demographic or lifestyle drivers fueling the MS market, it has experienced a breathtaking sales expansion during recent years. This growth has almost exclusively resulted from the commercialization of disease-modifying biotechnology drugs."
About Decision Resources
Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company provides strategic information services, and assesses international pharmaceutical and health care industry trends. Visit Decision Resources at http://www.decisionresources. com.
All company, brand, or product names contained in this document may
be trademarks or registered trademarks of their respective holders.
Copyright © 2003, PR Newswire Association LLC